Elicio Therapeutics, Inc. (ELTX) News
Track canonical SquawkNews coverage tagged to ELTX, Elicio Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Elicio Therapeutics Price Target Cut to $8.00/Share From $27.00 by B. Riley Securities
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:26 PM UTC
H
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. NASDAQ:ELTX (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, tod
GEOPOLITICS | Sep 24, 2026, 12:03 PM UTC
L
ELTX: ELI-002 immunotherapy shows strong early results and is advancing to new combination trials in KRAS cancers
The discussion highlighted advances in lymph node-targeted immunotherapy, with ELI-002 showing promising responses in metastatic pancreatic cancer and a strong safety profile. Upcoming trials will combine ELI-002 with RA
NEWS | Sep 14, 2026, 09:49 PM UTC
L
ELTX: ELI-002 immunotherapy shows strong early results in KRAS cancers, with new trials starting soon
The company is advancing lymph node-targeted immunotherapies, with ELI-002 showing promising responses in KRAS-mutant cancers and plans for a new phase I trial in metastatic pancreatic cancer. The platform's modularity s
NEWS | Sep 14, 2026, 09:31 PM UTC
L
Elicio Therapeutics reports Q2 2026 financial results, provides corporate updates
Elicio Therapeutics (ELTX) reports its second-quarter 2026 financial results and provides corporate updates, according to the TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
Elicio Therapeutics shares are trading lower after the company announced the pricing of its $15 million offering of 4,380,313 shares.
Elicio Therapeutics shares are trading lower after the company announced the pricing of its $15 million offering of 4,380,313 shares.
EQUITY | Jul 02, 2026, 11:52 AM UTC
L
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC
EQUITY | Jul 02, 2026, 06:26 AM UTC